Population Pharmacokinetics of Total and Protein-Unbound Prednisolone in Children with Immune-Mediated and Systemic Inflammatory Diseases
This population PK model provides valuable insights into PK variability of prednisolone and can be used to address the clinical implications of BW-based dosing of prednisolone in children with immune-mediated and inflammatory diseases.
Authors
- Matthijs van Luin (ORCID: https://orcid.org/0000-0001-8409-9316)
- Alwin D. R. Huitema (ORCID: https://orcid.org/0000-0003-1939-4639)
- Aurelia H. M. de Vries Schultink (ORCID: https://orcid.org/0000-0003-0960-062X)
- Marc H.A. Jansen (ORCID: https://orcid.org/0000-0001-6969-8759)
- Julia E. Möhlmann (ORCID: https://orcid.org/0000-0001-6496-937X)
- Caroline A. Lindemans (ORCID: https://orcid.org/0000-0002-3984-5620)
- Arjen M. Punt (ORCID: https://orcid.org/0000-0003-3336-1980)
- Stefan Nierkens (ORCID: https://orcid.org/0000-0003-3406-817X)
- Solaiman Ezzafzafi
Institutions
- Utrecht University (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Oncode Institute (NL)
- Princess Máxima Center (NL)
- Wilhelmina Children's Hospital (NL)
Publication Details
- Journal
- Clinical Pharmacokinetics
- Published
- 2025-12-11
- DOI
- https://doi.org/10.1007/s40262-025-01601-5
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00